menu
    • menu
    [{"orgOrder":0,"company":"Pendopharm","sponsor":"KalVista Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pendopharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pendopharm \/ Pendopharm Division of De Pharmascience Inc","highestDevelopmentStatusID":"15","companyTruncated":"Pendopharm \/ Pendopharm Division of De Pharmascience Inc"},{"orgOrder":0,"company":"Pendopharm","sponsor":"Pendopharm","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pendopharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Pendopharm \/ PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","highestDevelopmentStatusID":"15","companyTruncated":"Pendopharm \/ PENDOPHARM DIVISION OF DE PHARMASCIENCE INC"}]

    Find Clinical Drug Pipeline Developments & Deals by Pendopharm

    Menu

    Pendopharm

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pendopharm

                            Canada arrow
                            AAPS
                            Not Confirmed

                            Pendopharm

                            Canada arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sebetralstat

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Recipient : KalVista Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            KalVista Enters into Agreement with Pendopharm to Commercialize Sebetralstat in Canada

                            Details : Pendopharm has the exclusive rights to manage the regulatory approval process and commercialization of KVD900 (sebetralstat), an investigational, oral on-demand treatment for hereditary angioedema.

                            Product Name : KVD900

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 26, 2025

                            Lead Product(s) : Sebetralstat

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Recipient : KalVista Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pendopharm

                            Canada arrow
                            AAPS
                            Not Confirmed

                            Pendopharm

                            Canada arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Recipient : Montreal Heart Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Health Canada Approval of Low-Dose Colchicine for Cardiovascular Disease Based on The COLCOT Study

                            Details : Health Canada has issued a Notice of Compliance for the prescription drug MYINFLA™ (colchicine 0.5 mg tablets) based on the results of the Montreal Heart Institute (MHI)’s COLCOT clinical trial.

                            Product Name : Myinfla

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            August 27, 2021

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Montreal Heart Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth